Literature DB >> 19015953

Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.

Ashgan I El-Sarha1, Gehan M Magour, Sameh M Zaki, Mohamed Y El-Sammak.   

Abstract

Fas (CD95-APO-1), a member of tumor necrosis factor receptor super-family, exists in two forms, transmembrane and soluble (sFas). It had been suggested that circulating sFas levels and/or tissue FasL may reflect the severity of invasive breast ductal carcinoma. Few studies showed that neither DNA-index nor ploidy is an independent prognostic indicator, and there is no correlation with clinical outcome. The S-phase fraction (SPF) has been shown to be useful prognostic factor in both node-negative and node-positive tumors. The present work was done to find a correlation between sFas, tissue FasL, ploidy and SPF with prognostic factors and survival of breast ductal carcinoma patients. The present study included two groups; a patients group comprised 30 patients with breast ductal carcinoma and a control group that comprised 15 patients with benign breast swellings. Serum sFas was measured using commercially available ELISA kit and tissue FasL expression was studied using avidin-biotine immunohistochemical staining technique. Cell cycle studies were performed using flow cytometry. Serum sFas was significantly higher in breast ductal carcinoma group than in the benign breast swelling control group. A significant negative correlation between serum sFas and overall survival was found. Tissue FasL expression was directly correlated with distant metastasis and poor overall survival. A significant direct correlation was found between moderate and high SPF with worse pathologic parameters. Serum sFas level, tissue FasL immuno-expression and S-phase fraction are independent prognostic factors in breast ductal carcinoma cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015953     DOI: 10.1007/s12253-008-9109-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  47 in total

Review 1.  [New concepts for the study of anticancer drug resistance].

Authors:  Jacques Robert
Journal:  Bull Cancer       Date:  2002-01       Impact factor: 1.276

2.  Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.

Authors:  P Schneider; J L Bodmer; N Holler; C Mattmann; P Scuderi; A Terskikh; M C Peitsch; J Tschopp
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

3.  Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.

Authors:  H Nagashima; M Mori; N Sadanaga; K Mashino; Y Yoshikawa; K Sugimachi
Journal:  Int J Oncol       Date:  2001-06       Impact factor: 5.650

Review 4.  Clinical relevance of apoptotic markers in breast cancer not yet clear.

Authors:  J J Jager; R L H Jansen; J W Arends
Journal:  Apoptosis       Date:  2002-08       Impact factor: 4.677

5.  New observations on the Regan isoenzyme of alkaline phosphatase in cancer patients.

Authors:  L Nathanson; W H Fishman
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

6.  Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.

Authors:  T E Kute; Y Quadri; H Muss; N Zbieranski; C Cirrincione; D A Berry; M Barcos; A P Thor; E Liu; F Koerner
Journal:  Cytometry       Date:  1995-12-15

7.  Prognostic relevance of altered Fas (CD95)-system in human breast cancer.

Authors:  M Mottolese; S Buglioni; C Bracalenti; M A Cardarelli; L Ciabocco; D Giannarelli; C Botti; P G Natali; A Concetti; F M Venanzi
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

8.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

9.  Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer.

Authors:  G E Feichter; A Mueller; M Kaufmann; D Haag; I A Born; U Abel; K Klinga; F Kubli; K Goerttler
Journal:  Int J Cancer       Date:  1988-06-15       Impact factor: 7.396

10.  Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

Authors:  P Dettmar; N Harbeck; C Thomssen; L Pache; P Ziffer; K Fizi; F Jänicke; W Nathrath; M Schmitt; H Graeff; H Höfler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  2 in total

1.  The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3.

Authors:  Taha I Hewala; Nadia A Abd El-Monaim; Medhat Anwar; Samia A Ebied
Journal:  Pathol Oncol Res       Date:  2012-03-17       Impact factor: 3.201

2.  Predictors of responses to immune checkpoint blockade in advanced melanoma.

Authors:  N Jacquelot; M P Roberti; D P Enot; S Rusakiewicz; N Ternès; S Jegou; D M Woods; A L Sodré; M Hansen; Y Meirow; M Sade-Feldman; A Burra; S S Kwek; C Flament; M Messaoudene; C P M Duong; L Chen; B S Kwon; A C Anderson; V K Kuchroo; B Weide; F Aubin; C Borg; S Dalle; O Beatrix; M Ayyoub; B Balme; G Tomasic; A M Di Giacomo; M Maio; D Schadendorf; I Melero; B Dréno; A Khammari; R Dummer; M Levesque; Y Koguchi; L Fong; M Lotem; M Baniyash; H Schmidt; I M Svane; G Kroemer; A Marabelle; S Michiels; A Cavalcanti; M J Smyth; J S Weber; A M Eggermont; L Zitvogel
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.